The purpose of this study was to identify genetic variants predictive of cardiovascular risk factors in a psychiatric population treated with second generation antipsychotics (SGA). 924 patients undergoing treatment for severe mental illness at four US hospitals were genotyped at 1.2 million single nucleotide polymorphisms. Patients were assessed for fasting serum lipid (low density lipoprotein cholesterol [LDLc], high density lipoprotein cholesterol [HDLc], and triglycerides) and obesity phenotypes (body mass index, BMI). Thirteen candidate genes from previous studies of the same phenotypes in non-psychiatric populations were tested for association. We confirmed 8 of the 13 candidate genes at the 95% confidence level. An increased genetic effect size was observed for triglycerides in the psychiatric population compared to that in the cardiovascular population.
Introduction
Psychiatric patients face a substantial and potentially growing risk of metabolic syndrome and cardiovascular disease (Franciosi and Kasper, 2005; Newcomer, 2005) . Of the 57.7 million patients with diagnosable mental illness in the U.S. (NIMHS, 2009) , 30-70%, or 17 to 40 million, are estimated to have metabolic syndrome (Correll et al., 2006; Lamberti et al., 2006; Mackin et al., 2007; McEvoy et al., 2005) . The introduction of "second generation" antipsychotics (SGA) has coincided with a disproportionate increase in metabolic syndrome in patients with severe mental illness (Newcomer, 2005) . SGAs are approved in the U.S. for treatment of schizophrenia, bipolar disorder, psychotic depression and irritability in children with autistic disorder, but are increasingly being used for other psychoses, dementia, obsessive-compulsive and mood disorders in both adults and children (Barbui, 2004; Olfson et al., 2006) . SGAs collectively are now more widely utilized than first generation antipsychotic medications (Snyder and Murphy, 2008) . SGAs currently available in the U.S. include clozapine, olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole. SGAs are associated with unwanted metabolic side effects (MSE) including weight gain and glucose and lipid disturbances (Correll et al., 2009; Wampers et al., in press) , and patients receiving SGA therapy are 9% more likely to have diabetes mellitus than those treated with "first generation" antipsychotics (Sernyak et al., 2002) . Hypertriglyceridemia and hypercholesterolemia can develop in patients in as little as 3 months after initial exposure to these drugs (Meyer et al., 2006) .
The development of MSE in psychiatric patients at such rapid rates has become a serious problem in clinical psychiatry, mirroring concerns about the development of tardive dyskinesia in patients taking first generation anti-psychotic agents. Indeed, the development of weight gain, hyperlipidemia and diabetes mellitus may present threats to health as significant as the underlying disorders being treated and has already limited the use of SGAs for some patients. It is of clinical interest that MSE do not develop in all patients (Newcomer, 2005) and it would be of enormous clinical value to be able to predict vulnerable populations. Adverse drug effects are often related to genetic factors (Blanc et al., 2010; Foster et al., 2010; Gurwitz and McLeod, 2007) 
